Clinical Experience with Compression Taping to Treat Seroma After Breast Cancer Surgery: A Medical Device Clinical Study.

Autor:	Fabro EAN; At the National Cancer Institute, Rio de Janeiro, Brazil, Erica Alves Nogueira Fabro, MSc, PT, is Physical Therapist Manager, Physiotherapy Service, Cancer Hospital III; Clarice Gomes Chagas Teodózio, MSc, PT, is a PhD student, Oncology PhD Student Program; Rejane Medeiros Costa, PhD, PT, and Flávia Oliveira Macedo, MSc, PT, are Physical Therapists, Physiotherapy Service, Cancer Hospital III; Aline Cecilia Drumond Dutra Luz Machado Cardoso, BSc, and Raquel Barroso Evaldt Jacob, BSc, are nurses, Nursing Service, Cancer Hospital III; and Luiz Claudio Santos Thuler, MD, PhD, and Anke Bergmann, PhD, PT, are Researchers, Clinical Epidemiology Program. Acknowledgment: The authors thank Fisiovital (Indaiatuba, Sao Paolo, Brazil) for donating the Vitaltape bandage necessary for this research. The authors have disclosed no other financial relationships related to this article. Submitted May 19, 2021; accepted in revised form August 18, 2021., Teodózio CGC, Costa RM, Macedo FO, Cardoso ACDDLM, Jacob RBE, Thuler LCS, Bergmann A
Jazyk:	angličtina
Zdroj:	Advances in skin & wound care [Adv Skin Wound Care] 2022 Jul 01; Vol. 35 (7), pp. 1-6.
DOI:	10.1097/01.ASW.0000831068.34587.3d
Abstrakt:	Objective: To evaluate the safety of compressive taping in patients with seroma secondary to breast cancer surgery. Methods: This study was a nonrandomized clinical study of medical devices applied to women indicated for seroma aspiration puncture after breast cancer surgery in a public reference hospital in Brazil. The intervention consisted of applying compressive taping over the seroma fluctuation area and maintained for 5 days. Evaluated outcomes comprised dermal changes caused by taping, subjective symptoms reported during the intervention period, and percent change in the punctured volume before and after the intervention. Results: A total of 35 women (mean age, 56.7 ± 12.2 years) were included. Most presented with an advanced disease stage (≥IIB; 62.9%). Although a 28.6% incidence of dermal changes caused by taping was observed, an average reduction in the aspirated volume of -28.2 mL was identified (95% confidence interval, -48.3 to -8.0; P = .008). Treatment adherence was high (91.4%), and most patients reported satisfaction with the treatment (85.7%). Conclusions: The use of compressive taping on seroma areas can be considered safe, is well accepted by patients, and might be used as a noninvasive treatment option for seroma developing after breast cancer surgery. (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu